The results highlight our method’s capacity to directly select tumor-specific TCRs for therapy and suggest the mutant KRAS-specific TCRs as candidates for an off-the-shelf TCR-T therapy in HLA-A*01:01-positive patients with RAS Q61H-positive tumors. This evidence concerns the gene KRAS and neoplasm.